Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the Hong Kong Stock Exchange for the full circulation of its H shares. This approval allows the conversion of 25,421,196 domestic shares into H shares, increasing the proportion of H shares in the company’s total share capital from 57.83% to 69.02%. This strategic move is expected to enhance the company’s market liquidity and potentially attract more international investors, reflecting positively on its market positioning.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of biopharmaceutical products, with a market focus on both domestic and international stakeholders.
YTD Price Performance: 71.95%
Average Trading Volume: 517,801
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$59.19B
For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money